Polyphosphate modulates blood coagulation and fibrinolysis.

Inorganic polyphosphate is an abundant component of acidocalcisomes of bacteria and unicellular eukaryotes. Human platelet dense granules strongly resemble acidocalcisomes, and we recently showed that they contain substantial amounts of polyphosphate, which is secreted upon platelet activation. We now report that polyphosphate is a potent hemostatic regulator, accelerating blood clotting by activating the contact pathway and promoting the activation of factor V, which in turn results in abrogation of the function of the natural anticoagulant protein, tissue factor pathway inhibitor. Polyphosphate was also found to delay clot lysis by enhancing a natural antifibrinolytic agent, thrombin-activatable fibrinolysis inhibitor. Polyphosphate is unstable in blood or plasma, owing to the presence of phosphatases. We propose that polyphosphate released from platelets or microorganisms initially promotes clot formation and stability; subsequent degradation of polyphosphate by blood phosphatases fosters inhibition of clotting and activation of fibrinolysis during wound healing.

[1]  M. Boffa,et al.  Thrombin, Thrombomodulin and TAFI in the Molecular Link Between Coagulation and Fibrinolysis , 1997, Thrombosis and Haemostasis.

[2]  C. Sprung,et al.  Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. , 2003, JAMA.

[3]  A. Kornberg Inorganic polyphosphate: a molecule of many functions. , 2003, Annual review of biochemistry.

[4]  Wangxue Chen,et al.  Fibrin-mediated Protection Against Infection-stimulated Immunopathology , 2003, The Journal of experimental medicine.

[5]  J H Morrissey,et al.  Rapid and efficient incorporation of tissue factor into liposomes , 2004, Journal of thrombosis and haemostasis : JTH.

[6]  Peter Rohloff,et al.  Acidocalcisomes ? conserved from bacteria to man , 2005, Nature Reviews Microbiology.

[7]  E. Oldfield,et al.  Human Platelet Dense Granules Contain Polyphosphate and Are Similar to Acidocalcisomes of Bacteria and Unicellular Eukaryotes* , 2004, Journal of Biological Chemistry.

[8]  A. Mast,et al.  Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. , 1996, Blood.

[9]  A. Schmaier,et al.  Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. , 1997, Blood.

[10]  W. Gahl,et al.  Molecular defects that affect platelet dense granules. , 2004, Seminars in thrombosis and hemostasis.

[11]  M. Nesheim Thrombin and fibrinolysis. , 2003, Chest.

[12]  J. Morrissey,et al.  Properties of recombinant human thromboplastin that determine the International Sensitivity Index (ISI) , 2004, Journal of thrombosis and haemostasis : JTH.

[13]  J. Morser,et al.  TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex* , 1996, The Journal of Biological Chemistry.

[14]  D D Monkovic,et al.  Activation of human factor V by factor Xa and thrombin. , 1990, Biochemistry.

[15]  P. Neuenschwander,et al.  Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. , 1995, Biochemistry.

[16]  J. Miletich,et al.  Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor , 1988 .

[17]  H. Coenraad Hemker,et al.  Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[18]  J. Meijers,et al.  Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. , 2003, Blood.

[19]  L. Björck,et al.  Activation of the contact-phase system on bacterial surfaces—a clue to serious complications in infectious diseases , 1998, Nature Medicine.

[20]  J. Silveira,et al.  Unique in Vivo Modifications of Coagulation Factor V Produce a Physically and Functionally Distinct Platelet-derived Cofactor , 2004, Journal of Biological Chemistry.

[21]  H. Schröder,et al.  Anti-HIV-1 activity of inorganic polyphosphates. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[22]  Ping Wang,et al.  Thrombin activatable fibrinolysis inhibitor: Not just an inhibitor of fibrinolysis , 2004, Critical care medicine.

[23]  R. W. Kuhn,et al.  Purification and properties of a carboxypeptidase inhibitor from potatoes. , 1974, The Journal of biological chemistry.

[24]  P. Carmeliet,et al.  Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. , 1998, Thrombosis research.

[25]  B. Lorenz,et al.  Mammalian intestinal alkaline phosphatase acts as highly active exopolyphosphatase. , 2001, Biochimica et biophysica acta.

[26]  S. Opal Interactions between Coagulation and Inflammation , 2003, Scandinavian journal of infectious diseases.

[27]  P. Simioni,et al.  Megakaryocytes endocytose and subsequently modify human factor V in vivo to form the entire pool of a unique platelet‐derived cofactor , 2005, Journal of thrombosis and haemostasis : JTH.

[28]  G. Broze,et al.  Tissue Factor Pathway Inhibitor , 1995, Thrombosis and Haemostasis.